Damora Therapeutics Inc. Common Stock
Financials
Valuation Metrics
Damora Therapeutics Inc. Common Stock's Market Cap is $1.33B. At end of 2025 it was $31M. Ranked #2251 of 3,118 in US market (top 72%), #897 of 1,474 on NASDAQ (top 61%), #166 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 63%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.33B | US#2,251/3,118 Sec#166/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-263M | US—/3,118 Sec—/265 |
| Total Assets | $544M | US#2,725/3,118 Sec#153/265 |
| Net Assets | $516M | US#2,210/3,118 Sec#107/265 |
| Employees | 7 | US#2,777/3,118 Sec#223/265 |
| Value | ||
| P/B | 2.58x | US#1,594/3,118 Sec#81/265 |
| Profitability | ||
| ROE | -50.93% | US#2,672/3,118 Sec#157/265 |
| ROA | -48.35% | US#2,975/3,118 Sec#208/265 |
| Financial Health | ||
| Debt Ratio | 5.34% | US#41/3,118 Sec#15/265 |
| Total Debt | $0.00 | US—/3,118 Sec—/265 |
| Cash | $541M | US#1,023/3,118 Sec#55/265 |
| Current Ratio | 19.73x | US#118/3,118 Sec#26/265 |
| Performance | ||
| 1Y Return | 195.08% | US#35/3,118 Sec#13/265 |
| 1M Return | 4.60% | US#1,659/3,118 Sec#105/265 |
| From 52W High | -43.65% | US#2,470/3,118 Sec#179/265 |
| 1Y MDD | -46.87% | US#2,256/3,118 Sec#150/265 |
| Trading | ||
| Volume | 468,238 shares | US#2,550/3,118 Sec#241/265 |
| Trading Value | $10M | US#2,608/3,118 Sec#208/265 |
| Per Share | ||
| EPS | $-4.27 | US—/3,118 Sec—/265 |
| BPS | $8.38 | US#1,954/3,118 Sec#81/265 |
Company Info
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.